The current guidelines for NSCLC recommend frontline comprehensive testing of all known actionable driver biomarkers including EGFR, ALK, ROS1, BRAF, KRAS, NTRK, MET, RET, HER2 [ERBB2], and PD-L1 with higher relevance in advanced disease stages, to choose the most appropriate targeted therapy for a patient (4, 5). Here, ALK is linked to non-small cell lung carcinoma.